Peran Neuroprotektor Astaxanthin dalam Pencegahan Penyakit Alzheimer
DOI:
https://doi.org/10.32584/jikj.v3i1.469Keywords:
alzheimer, astaxanthin, neuroprotektorAbstract
Alzheimer merupakan penyakit neurodegeneratif yang terjadi secara bertahap dan progresif disebabkan oleh kematian sel neuron. Bertambahnya usia, cidera kepala traumatis, depresi, penyakit kardiovaskular dan serebrovaskular, usia orang tua yang lebih tinggi, merokok, riwayat keluarga demensia dapat meningkatkan risiko penyakit. Alzheimer tidak dapat disembuhkan, namun terdapat beberapa obat yang dapat mengatasi gejala simptomatis dari penyakit ini seperti inhibitor colinesterase dan N-metil D-aspartat (NMDA) parsial. Astaxanthin diketahui memiliki kandungan antioksidan dan antiinflamasi sepuluh kali lebih kuat dari kelompok karoten lain. Sehingga dapat menjadi neuroprotektor dengan meningkatkan pembersihan Aβ, melindungi viabilitas sel dari kerusakan yang disebabkan oleh Ab25-35, dan menghambat ekspresi IL-1b dan TNF-a. Tujuan dari tinjauan pustaka ini adalah untuk melaporkan temuan ilmiah terbaru tentang peran protektif dan kuratif astaxanthin pada otak manusia terhadap peradangan saraf, stres oksidatif dan, lebih umum, pada efek menguntungkan bagi pasien dengan gangguan neurodegeneratif seperti Alzheimer. Metode yang digunakan dalam artikel ini adalah penelusuran artikel melaui database NCBI dan Google Scholar. Tahun penerbitan sumber pustaka adalah dari tahun 1997 sampai tahun 2019 dengan 24 sumber pustaka. Tema yang dikumpulkan terkait dengan mekanisme neuroprotektor astaxanthin terhadap Alzheimer. Hasil dari sintesis artikel yang telah ditemukan yaitu astaxanthin dapat mencegah kerusakans sel otak sebagai pencegahan Alzheimer. Kata kunci: alzheimer, astaxanthin, neuroprotektor THE ROLE OF NEUROPROTECTOR ASTAXANTHIN AGAINST ALZHEIMER DISEASE ABSTRACTAlzheimer's is a neurodegenerative disease that occurs gradually and progressively caused by neuronal cell death. Increasing age, traumatic head injury, depression, cardiovascular and cerebrovascular diseases, higher age of parents, smoking, family history of dementia can increase disease. Alzheimer's cannot be cured, but there are some drugs that can overcome the symptomatic of this disease such as colinesterase inhibitors and partial N-methyl D-aspartate (NMDA). astaxanthin has higher antioxidant and anti-inflammatory properties than other carotene groups. Can be used as a neuroprotector by increasing Aβ regulation, protecting cell viability from damage caused by Ab25-35, and inhibiting the repair of IL-1b and TNF-a. The purpose of this literature evaluation is to report the latest scientific findings on the protective and curative role of astaxanthin in the human brain against nerve inflammation, oxidative stress and, more generally, on beneficial effects for patients with neurodegeneratives such as Alzheimer's. The method used in this article is article searching through the NCBI database and Google Scholar. Last year the library sources were from 1997 to 2019 with 24 library sources. The theme collected is related to the astaxanthin neuroprotector transition to Alzheimer's. The results of the synthesis of articles that have been found is that astaxanthin can prevent brain cell damage as against Alzheimer's. Keywords: alzheimer, astaxanthin, neuroprotectorReferences
Alzheimer's Disease International. (2015). World alzheimer's Rreport 2015, the global impact of demensia, an analysis of prevalence, Iincidence, cost and trends. Alzheimer's Disease International.
Bird, T.D. (2018). Alzheimer disease overview. GeneReviews [Internet] tersedia dari: https://www.ncbi.nlm.nih.gov/books/NBK1161/
Capelli, B. and Cysewski, R. (2007). Natural astaxanthin: king of the carotenoid. USA; Cyanotech Corporation.
Chang, C.H., Chen, C.Y., Chiou, J.Y., Peng, R.Y., Peng, C.H. 2010. Astaxanthine secured apoptotic death of PC12 cells induced by b-amyloid peptide 25–35: Its molecular action targets. J Med Food 13 (3) 548–556. Mary Ann Liebert, Inc. and Korean Society of Food Science and Nutrition. DOI: 10.1089=jmf.2009.1291
Che H., Li Q., Zhang T., Wang D., Yang, L., Xu, J., Yanagita, T., Xue, C., Chang, Y., Wang, Y. (2018). Effects of astaxanthin and docosahexaenoic-acid-acylated astaxanthin on alzheimer's disease in APP/PS1 double-transgenic mice. Journal of Agric Food Chem. May 16; 66(19):4948-4957.
Cho, K.S., Shin, M., Kim, S., Lee, S.B. Recent advances in studies on the therapeutic potential of dietary carotenoids in neurodegenerative diseases. Oxid. Med. Cell. Longev. 2018:4120458. doi: 10.1155/2018/4120458
Craft, N.E., Haitema, T.B., Garnett, K.M., Fitch, K.A., Dorey, C.K. (2004). Carotenoid, tocopherol, and retinol concentrations in elderly human brain.J Nutr Health Aging. 8(3):156-62.
Fanaee-Danesh, E., Gali, C.C., Tadic, J., Zandl-Lang, M., Kober, A., Agujetas, V.R., Panzenboeck, U. (2019). Astaxanthin exerts protective effects similar to bexarotene in Alzheimer’s disease by modulating amyloid beta and cholesterol homeostasis in blood-brain barrier endothelial cells. Biochimica et Biophysica Acta (BBA). Molecular Basis of Disease. Doi:10.1016/j.bbadis.2019.04.019
Furr, H.C., Clark, R.M.(1997). Intestinal absorption and tissue distribution of carotenoids. J Nutr Biochem. 8:364–377. doi: 10.1016/S0955-2863(97)00060-0
Galasso, C., Orefice, I., Pellone, P., Cirino, P., Miele, R., Lanora, A. Brunet, C., Sansone, C. (2018) On the neuroprotective role of astaxanthin: new perspectives. Mar Drugs. Aug; 16(8): 247. doi: 10.3390/md16080247
Guerin, M., Mark, E.H., and Miguel, O. (2003). Haematococcus astaxanthin: applications for human health and nutrition. Trends In Biotechnology Vol.21 No.5 May.
Hussein, W., Sağlık, B.N., Levent, S., Korkut, B., Ilgın, S., Özkay, Y., Kaplancıklı, Z.A. (2018) Synthesis and biological evaluation of new cholinesterase inhibitors for alzheimer's disease. Molecules. Aug 14;23(8).
Kim Y.H., Koh H.K., Kim D.S. (2010). Down-regulation of IL-6 production by astaxanthin via ERK-, MSK-, and NF-κB-mediated signals in activated microglia. Int. Immunopharmacol. 10:1560–1572. doi: 10.1016/j.intimp.2010.09.007
Khoury, R., Grysman, N., Gold, J., Patel, K., Grossberg, G.T. (2018). The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update. Expert Opin Investig Drugs. Jun; 27(6):523-33
Koutsilieri, E., Scheller, C., Tribl, F., Riederer, P. (2002). Degeneration of neuronal cells due to oxidative stress--microglial contribution. Parkinsonism Relat Disord.Sep; 8(6):401-6.
Kumar, A., Tsao, J.W. (2018). A review of alzheimer disease. StatPearls Publishing LLC. https://www.ncbi.nlm.nih.gov/books/NBK499922/
Liljegren M., Landqvist W.M., Rydbeck R., Englund E. (2018) Police interactions among neuropathologically confirmed dementia patients: prevalence and cause. Alzheimer Dis Assoc Disord. Oct-Dec;32(4):346-350.
Lorenz, R.T. and Cysewski, G.R. (2000). Commercial potential for Haematococcus microalgae as a natural source of astaxanthin. Trends Biotechnol. 18, 160–167.
Naguib, Y.M.A. (2000). Antioxidant activities of astaxanthin and related carotenoid biosynthetic genes during maturation in citrys fruit. Journal of American Society of Plant Biologist. 2 (134): 824-37
Odeberg, J., Lignell, A., Pettersson, A., Höglund, P. (2003). Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations. Eur J Pharm Sci. Jul; 19(4):299-304.
Satoh A., Tsuji S., Okada Y., Murakami N., Urami M., Nakagawa K., Ishikura M., Katagiri M., Koga Y., Shirasawa T. (2009). Preliminary clinical evaluation of toxicity and efficacy of a new astaxanthin-rich Haematococcus pluvialis extract. J. Clin. Biochem. Nutr. 44:280–284. doi: 10.3164/jcbn.08-238.
Schachter A.S., Davis K.L. (1999). Guidelines for the appropriate use of cholinesterase inhibitors in patients with Alzheimer's disease. CNS Drugs. 11:281–288
Suriastini, W., Turana Y, Suryani L K., Sukadana, W., Sikoki, B.,Witoelar, F., et al. (2018). Laporan hasil studi demensia bali 2018. Bali; Universitas Udayana.
Wen X., Huang A., Hu J., Zhong Z., Liu Y., Li Z., Pan X., Liu Z. (2015). Neuroprotective effect of astaxanthin against glutamate induced cytotoxicity in HT22 cells: Involvement of the Akt/GSK-3β pathway. Neuroscience. Sep 10; 303():558-68.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
This work is licensed under a Creative Commons Attribution 4.0 International License.
